Current status of experimental therapeutics for prostate cancer
- 8 August 2008
- journal article
- review article
- Published by Elsevier BV in Cancer Letters
- Vol. 266 (2), 116-134
- https://doi.org/10.1016/j.canlet.2008.02.065
Abstract
No abstract availableKeywords
This publication has 79 references indexed in Scilit:
- Five-year Follow-up of Trial of Replication-competent Adenovirus-mediated Suicide Gene Therapy for Treatment of Prostate CancerMolecular Therapy, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitorApoptosis, 2005
- A Small Molecule Smac Mimic Potentiates TRAIL- and TNFα-Mediated Cell DeathScience, 2004
- Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complexCancer Cell, 2004
- Cyclooxygenase-2 as a Potential Target in the Prevention and Treatment of Genitourinary Tumors: A ReviewJournal of Urology, 2003
- Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplantsThe FASEB Journal, 2002
- Interleukin 2 Gene Therapy for Prostate Cancer: Phase I Clinical Trial and Basic BiologyHuman Gene Therapy, 2001
- SUICIDE GENE THERAPY TOXICITY AFTER MULTIPLE AND REPEAT INJECTIONS IN PATIENTS WITH LOCALIZED PROSTATE CANCERJournal of Urology, 2000
- Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphataseFEBS Letters, 1988